Document is current
Any future updates will be listed below
-
Authors
Voran, Jakob Christoph
Richard, Carolin
Dempfle, Astrid
Pott, Christiane
Nakov, Philipp
Chitadze, Guranda
Schub, Natalie
Meyer, Catrin
Seoudy, Hatim
Frank, Derk
Baldus, Claudia D
Müller, Oliver J
Baden, David
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 7 May 2026
Accepted: 13 July 2026
First Online: 30 July 2026
Declarations
Ethics approval and consent to participate: The study was approved on November 1st, 2024, by the Ethics Committee of the Medical Faculty at Kiel University (D 610/24). As this was a retrospective analysis of pseudonymized routinely collected data, the ethics committee waived the requirement for individual patient consent.
Competing interests: CDB received support for travel expenses and honoraria from Janssen, Amgen, Novartis, Jazz, BMS; DB received support for travel expenses by SERVIER and Janssen-Cilag. JCV received honoraria from AstraZeneca. OM received honoraria from Novartis, BMS and Pfizer, payment from the European Commission and holds a position as Board member of the German Society of Angiology - Society for Vascular Medicine.All other authors have no relevant financial or non-financial interests to disclose.
